SCOPE
This
policy applies to the following in their roles overseeing, reviewing or conducting
UC San Diego human subjects research:
·
the
Institutional Official for protection of human subjects
·
Institutional
Review Boards (IRBs)
·
Researchers
(and any Staff, Students or other individuals working under their direction)
·
Department
Chairs
·
Office
of IRB Administration (OIA)
To the
extent that they incidentally oversee human subjects research as part of
broader duties, other UC San Diego offices, committees or personnel should be
aware of this policy and collaborate with the entities listed above in the
protection of human subjects.
All of
the above have a shared commitment and responsibility to protect the rights and
welfare of research subjects and together constitute the UC San Diego Human
Research Protection Program (HRPP).
POLICY
SUMMARY
UC
San Diego and its employees share the responsibility to protect research
subjects by following the ethical principles of the Belmont Report (1979)
as operationalized by applicable regulations. Those principles are:
·
Respect
for Persons (recognizing the personal dignity and autonomy of individuals and providing
special protection for those with diminished autonomy)
·
Beneficence
(minimizing possible risk of harm while maximizing anticipated benefits)
·
Justice
(fairness in the distribution of benefits and harms of research)
University
of California policy applies the Common Rule or commensurate protections
to all human subjects research in which UC San Diego is engaged, regardless of
funding source, funding status, the location, or scale of the research.
Additional
regulations or policies may apply depending on, for example, whether Food and
Drug Administration (FDA)-regulated products are involved, state laws cover particular
populations, or a sponsor places additional conditions on funding. In the event
that different applicable regulations and/or requirements conflict, the more
restrictive regulations and/or requirements shall prevail.
This
policy describes the authorities and responsibilities of various parties in protecting
human subjects.
DEFINITIONS
Clinical
Investigation:
Any experiment that involves a test article and one or more human subjects and
that either is subject to requirements for prior submission to the FDA under
section 505(i) or 520(g) of the Food, Drug, and Cosmetic Act, or is not subject
to requirements for prior submission to the FDA under these sections of the FDCA,
but the results of which are intended to be submitted later to, or held for
inspection by, the FDA as part of an application for a research or marketing
permit.
Common
Rule:
The Federal Policy for the Protection of Human Subjects as adopted into
regulation by multiple federal agencies, including the Department of Health and
Human Services (DHHS), National Science Foundation (NSF) and Department of
Defense (DOD). For ease when citing specific provisions of the Common Rule,
this policy and related policy, guidance, or procedure documents will generally
refer to DHHS regulations at Title 45, Part 46, Subpart A of the Code of
Federal Regulations (45 CFR 46).
Engagement: Generally, when UC
San Diego is the prime awardee of funding for Human
Subjects Research or when individuals exercise UC San Diego-granted
authority or responsibility or perform UC San Diego-designated activities for human
subjects research or obtain informed consent for human subjects research.
Exempt: Activities that constitute
human subjects research but do not require IRB review because they have been
administratively certified as 1) fitting into one or more exempt categories in
applicable regulations, 2) not otherwise limited by regulation or policy, AND
3) meeting UC San Diego ethical standards as set out by OIA.
Human
Research Protection Program: Those entities referred to by the Scope section of this
policy (not to be confused with the former name of the OIA).
Human Subject: A living individual about whom an
investigator (whether professional or student) conducting research (1) obtains information
or biospecimens through intervention or interaction with the individual, and
uses, studies, or analyzes the information or biospecimens; or (2) obtains,
uses, studies, analyzes or generates identifiable private information or
identifiable biospecimens. For FDA-regulated research, “human subject” includes
an individual (or their specimens in the case of device research) who is either
the recipient of a test article or a control, whether patient or healthy
individual.
Human Subjects
Research:
An activity that is either (a) “research” as defined below AND involves one or
more “human subjects” as defined above or (b) a “clinical investigation” as
defined above. “Clinical investigations” for treatment purposes (without research
aims) are not considered “human subjects research” but this policy is
applicable to the extent required by FDA regulations.
Institutional
Official (IO):
The official to whom the Chancellor delegates authority to sign assurances of, and
to oversee the University's responsibility for, the protection of human subjects.
Institutional
Review Board (IRB):
A board established in accordance with and for the purposes expressed in the
Common Rule and FDA regulations. For the purposes of this policy, a UC San
Diego IRB is any IRB:
·
operated
by UC San Diego and designated under UC San Diego's Federalwide Assurance; or,
·
operated
by another institution but reviewing on behalf of the University with the agreement
of the Institutional Official (or designee).
Principal
Investigator (PI):
The person working on behalf of UC San Diego who is responsible for the ethical
conduct of the research and for carrying out the responsibilities described in
this policy. Generally, in order to serve in this capacity for human subject
protections an individual must be eligible under UC San Diego policy to submit
proposals for extramural support and serve as PI. The protocol PI (for human subject
protection purposes) does not have to be the same person as the award PI (for funding
purposes).
Research: A systematic
investigation, including research development, testing and evaluation, designed
to develop or contribute to generalizable knowledge.
Undue
influence: The
deliberate use of improper means (such as intimidation, deception, bribery or
exploitation of a vulnerability) to attempt or achieve improper ends (such as
getting IRB staff or members to disregard legal responsibilities or
institutional policy). Influence is not undue if it consists only of 1)
persuading, disagreeing or criticizing, 2) using proper channels to change, or
seek exceptions from, requirements or processes, or 3) disclosing, preventing
or correcting improper or inefficient exercise of IRB authority.
POLICY
STATEMENT
a) Overall Policy
1. UC San Diego and its employees
share responsibility for protecting human subjects according to the requirements
of applicable regulations and University policies.
2. University of
California policy applies the Common Rule or commensurate protections to all human
subjects research in which UC San Diego is engaged.
3. This policy on
Protection of Human Research Subjects applies to all human subjects research in
which UC San Diego is engaged, regardless of funding source, funding status, or
the location or scale of the Research.
4. Additional regulations
or policies may apply. In case of conflict between applicable regulations, the
more restrictive regulations prevail.
b) Commensurate
Protections
1. Consistent with
University of California systemwide policy, IO has the authority to approve alternatives
to specific Common Rule requirements for research that is not otherwise subject
to the Common Rule (for example, provisions relating to the Federal
government's role as a funder of research may be impossible to follow for
unfunded research). The OIA has the responsibility to ensure that such alternatives
provide commensurate protection to subjects and do not conflict with other applicable
regulations. OIA will be responsible to maintain written documentation of the
rationale and the approved alternative requirements.
2. For situations in which
FDA regulations require IRB review of treatment and there are no research aims
associated with such treatment (e.g., expanded access to investigational
products; devices that may be marketed under Humanitarian Use Device status), the
IRB will use a modified process consistent with prevailing FDA guidance for efficiency
while ensuring regulatory requirements are met. OIA will be responsible to
maintain written documentation of the rationale and the approved modified
process(es).
c) Jurisdiction of the
Human Research Protection Program
1. The UC San Diego HRPP
covers all UC San Diego engagement in human subjects research.
i. The HRPP does not
normally cover human subjects research in which UC San Diego is not engaged. In
rare cases, the IO may agree to extend the UC San Diego HRPP to cover
unaffiliated individual investigators collaborating with UC San Diego. Such an
arrangement requires a formal agreement and the active involvement of the UC
San Diego PI and approval by the VCR.
ii. If another institution
or unaffiliated research investigator relies on UC San Diego IRB review
services, a documented arrangement is required. Unless explicitly agreed, UC
San Diego is not responsible for on-site monitoring or conduct of the research
by another institution or unaffiliated investigators relying on UC San Diego
IRB review services.
2. Researchers might determine
that their activities do not constitute human subjects research or do not
engage UC San Diego, or researchers may request such a determination by OIA. Only
OIA may provide official determinations on behalf of UC San Diego.
i. The IO may also
delegate such authority to other units, subject to appropriate training,
documentation and audit standards (e.g., Health System QA/QI program). IO shall
periodically assess delegation and may revoke or limit any such delegation.
ii. Consistent with
requirements of this policy, OIA shall provide guidance and tools so that
decisions made by OIA or others are based on regulatory and University criteria
and are made efficiently.
d) Certification of Exemption
from IRB Review
1. When UC San Diego is
engaged in human subjects research, only individuals authorized under this
Policy and not otherwise associated with the project may certify a project as
exempt from IRB review.
i. UC San Diego uses all permissible
exemption categories.
ii. The IO may authorize creation
of additional exemption categories for use with projects that are eligible for
commensurate protections.
iii. Any additional
exemption categories shall be consistent with the nature and risk of the categories
used in regulations.
2. Certification of
exemption relates only to UC San Diego IRB review. Researchers (and
individuals working on their behalf) may not express or imply that a
certification exempts research from other applicable legal or institutional
requirements.
3. IO and Director of OIA are
each authorized to:
i. Certify projects as
exempt from IRB review.
ii. Accept another
institution's exemption certification as sufficient for UC San Diego.
iii. Permit the use of a
validated self-certification tool.
iv. Delegate the above
authorities to appropriate units, contingent upon ongoing compliance with training,
documentation and audit standards.
v. Limit or revoke delegations
of the above authorities for serious and/or continuing failure to comply with
training, documentation and audit standards.
e) IRB Authority
1. For all proposed human
subjects research in which UC San Diego is engaged that is not otherwise exempt
from IRB review, a UC San Diego IRB has authority to:
i. Approve or disapprove.
ii. Require modifications
in order to secure IRB approval.
iii. Suspend or terminate
its approval.
iv. Observe (or have a
third party observe) the consent process or the research.
v. Grant waivers related
to informed consent.
vi. Grant waivers related
to authorization under the Health Insurance Portability and Accountability Act
(HIPAA).
vii. Review eligible
research via the expedited process described in 45 CFR 46.110 and 21 CFR 56.110.
2. Consistent with the Responsibilities
section of this Policy, IO may delegate additional authorities to the IRB (for
example, authority to make determinations of “serious non-compliance”).
3. UC San Diego IRBs shall
exercise the above authorities only in accordance with criteria established by
federal or state regulation for human subject protections, the advice of campus
authorities University of
California policy, and/or properly promulgated UC San Diego policy.
i. When presented with
matters outside their scope of authority, the IRBs shall ask the Director of
OIA to refer such matters to other appropriate offices.
ii. The Director of OIA and
IRB Chairs will seek advice of University Counsel, the IO and/or the Vice
Chancellor for Research (VCR) as needed.
4. To maintain high
standards while providing effective and efficient service to researchers, UC
San Diego IRBs make use of flexibility offered by regulations and policies.
Examples include, but are not limited to, expedited review for minimal risk
research or waivers related to consent.
i. UC San Diego IRBs shall
generally offer or grant flexibilities when appropriate for eligible studies
even if a PI does not request such flexibilities. Some examples of this
include, but are not limited to:
1. Regardless of level of
review requested by the Principal Investigator, the expedited review process may
be used if the study is eligible.
2. If a study is eligible
for a waiver of signed informed consent but the study team fails to request
this explicitly, the IRB may grant a waiver of signed informed consent, as
appropriate.
ii. UC San Diego IRBs retain
the authority to make protocol-specific determinations that flexibility would
not provide adequate subject protection.
1. Such determinations must
be documented, including protocol-specific justifications for the
determinations.
2. When such determinations
are discussed at convened IRB meetings, the Chair shall call a specific vote. In
order for the proposal to pass, a majority of the quorum must approve the proposal.
5. When reviewing on
behalf of another institution, a UC San Diego IRB:
i. May exercise additional
authorities explicitly granted by that institution in its policies and/or in
the reliance agreement.
ii. May be prohibited from
exercising authorities e(1)v-vii and e(2) above.
iii. Shall apply local
requirements of that institution and/or the research location instead of UC or California-specific
requirements.
6. IRB approval does not
substitute for other approvals required by law or other university requirements.
7. Officials of the institution
may not approve human subjects research that does not have IRB approval.
i. UC San Diego interprets
this regulatory requirement to mean that the institution may not allow the human
subjects research portions of a project to proceed without IRB approval. However,
other review bodies may issue approvals and other activities not involving human
subjects may proceed, presuming that all required approvals applicable to those
activities have been secured (e.g., IACUC approval for animal research).
ii. Under exceptional
circumstances and with the concurrence of the VCR, the IO may seek second
consideration of an IRB's decision. Such consideration may be by the same IRB
or by a second IRB, internal or external to UC San Diego.
1. Consistent with federal
guidance, if the decision was disapproval a second IRB must be informed of that
disapproval and be given pertinent information about the initial disapproval.
2. Exceptional
circumstances may include, for example, 1) failure to reach timely
determinations, 2) individual or institutional conflicts of interest, or 3)
appeals by the IRB, the Director of OIA or the PI.
8. In reviewing non-compliance
or other problems in a human subjects research project, an IRB:
i. Shall:
1. Conduct a preliminary assessment
of the report in a timely fashion (generally within 30 days of receipt).
Preliminary assessment may be performed by a designated reviewer (eg, an IRB
Chair, the Director or Medical Director of OIA, or other qualified IRB member
designated by the above).
2. Determine whether immediate
or long-term measures are necessary to stop or prevent harm to current or
future subjects, including but not limited to temporarily suspending protocols.
A designated reviewer conducting a preliminary assessment may only take such
actions to stop or prevent immediate harm.
3. Determine whether to
require modifications to research protocols.
4. Determine whether to
require notification to current or past human research subjects.
5. Determine whether to
suspend or terminate approval of the research project.
6. Notify other
institutional offices as applicable (for example, where a report suggests
research misconduct).
7. Complete its review of
the matter in a timely fashion, generally within 90 days subject to factors
such as complexity, cooperativeness of individuals involved, active evaluation
by another unit, or other just cause.
ii. May:
1. Request that an
independent unit audit, review, or investigate the matter.
2. Impose measures the IRB
deems reasonably necessary to protect human research subjects in any UC San
Diego study where a nexus exists between the study and the alleged
noncompliance or other problem, for example where the same personnel,
facilities, or investigational products are involved.
3. Recommend disciplinary or
other actions related to the academic or research mission (such as publication retractions
or limitations on data use) and ask the Director of OIA to provide the
recommendation to the IO or other University officials; however the IRB has no
authority to require or impose such actions .
f) Protection from Undue
Influence
1. Attempts to unduly
influence UC San Diego IRBs or OIA staff constitute a serious violation of this
Policy and may result in discipline.
2. The Director of OIA shall
develop a procedure for handling reports and shall normally be the initial
point of contact for such reports, except that reports about the actions of the
Director of OIA should instead go to the IO. When reports are about a senior
institutional official, the Director of OIA shall refer reports to that
officer's supervisor (for example, the Chancellor for a report about a Vice
Chancellor).
g) Policies, Guidance and
Operating Procedures:
1. Effective on the
issuance date of this policy, all extant policy statements published or cited
by the IRBs or OIA are considered guidance instead of policy.
i. These include but are
not limited to “Standard Operating Policies & Procedures (SOPPs),” “FAQs”
and “Fact Sheets.”
ii. This policy does not change,
expand or reduce the applicability of regulatory requirements, advice of
counsel, and University policies mentioned or referred to in those statements.
iii. This policy does not
limit properly exercised IRB authority to require safeguards reasonably
necessary for a given project.
2. The OIA is charged with
establishing a process for proper and regular revision of guidance and operational
procedures on a recurring basis of no less than once per five years. This
process shall include requirements for:
i. Stakeholder consultation
ii. Approval of the IO, with
any necessary consultation with the VCR and/or the Chancellor.
RESPONSIBILITIES
a) Institutional Official
1. Sign and uphold the
Federalwide Assurance and any other required assurances.
2. Provide adequate resources
and space for the IRBs and their staff to carry out duties.
3. Appoint and remove IRB
members consistent with any applicable UC San Diego procedures. Designate Chairs
and Vice Chairs. Set performance expectations and terms of reasonable duration.
Member terms shall be no more than four years at a time, with renewal only by
mutual agreement of the IO and the member.
4. Regularly evaluate
expertise needs and performance of the IRBs and their members and adjust
membership accordingly.
5. Enter into agreements
for external IRBs to review Human Subjects Research on behalf of UC San Diego;
or for UC San Diego IRBs to review Human Subjects Research on behalf of other
institutions, seeking advice from the Office of Campus Counsel and other campus
officials as needed, as may be the case when agreements require novel indemnity
or institutional liability terms.
6.
Serve
as approval authority for IRB Guidance and Operating Procedures under this Policy.
7. Establish procedures to
promptly and fairly resolve questions, complaints, or reports related to
noncompliance with this Policy, noncompliance with IRB requirements, or threats
to the rights and safety of human research subjects.
i. IO has the authority
and responsibility to make, or to delegate the making of, regulatory
determinations such as “unanticipated problem involving risk to subjects or
others,” “serious non-compliance” and/or “continuing non-compliance”.
ii. Operational details of
any such delegation, whether to an IRB or to another entity, shall be
consistent with applicable UC or UC San Diego policies or procedures.
8. Make reports to
oversight agencies as required by regulation. When the VCR is not also IO, the
IO shall notify the VCR of all such reports as well as those reports from OIA
that do not need to be forwarded to oversight agencies.
9. Take actions pertaining
to IRB approved studies to protect human research subjects, including but not
limited to suspensions of studies and/or research activities. When the VCR is
not also IO, the IO shall notify and discuss such actions with the VCR.
10. Refer to the
appropriate Vice Chancellor, Dean, Chair, Chief, Director or Unit Head any matters
of discipline related to non-compliance with this policy or Code of Conduct and
recommend appropriate remedial actions.
11. Protect regulatory
independence of the IRB and respond to reports of undue influence upon the IRB
or the OIA.
12. Establish and publish
standards for training in human research protections, consulting and coordinating
with relevant parts of the HRPP.
13. When the VCR is not
also IO, the IO shall consult with the VCR of matters that involve significant
institutional risk, impact on academic appointments, or inquiries from outside
entities or agencies about possible non-compliance.
b) Institutional Review
Boards
1. Receive submissions and
perform timely, collegial reviews of human subject protections in a
risk-proportionate manner and in accordance with criteria established by
regulation and policy.
2. Exercise only those authorities
established by regulation, this policy, or otherwise explicitly granted by the
Institutional Official.
3. Exercise authority in a
manner that promotes respect for the Boards' advice and counsel; the IRBs shall
follow all applicable regulations and this Policy in their performance and
operations, and the IRBs shall not create new policies or practices without
appropriate delegated authority.
c) IRB Chairs and Vice
Chairs (UC San Diego-operated IRBs only)
1. Meet at least once per
year to:
i. Discuss issues and
operational challenges of common interest
ii. Maintain an appropriate
consistency across boards
iii. Formulate policy
recommendations to IO.
2. Manage regular and ad
hoc IRB meetings.
3. Perform expedited
reviews and designate additional expedited reviewers.
4. Collaborate with
Director of OIA to provide the IO with feedback about performance of IRB
members.
d) Researchers (and any
Staff, Students, or other individuals working under their direction)
1. Protect human subject
safety, rights, and welfare as per University requirements and the ethical
standards of their discipline. PIs are responsible for human subject safety,
rights, and welfare at all times, even if they delegate performance of tasks to
others.
2. Identify when their activities
engage UC San Diego in human subjects research and seek formal determination from
the OIA when unclear.
3. Obtain prospective
review and either UC San Diego IRB approval or UC San Diego certification of
exemption before:
i. Conducting new UC San
Diego human subjects research;
ii. Implementing any changes
to UC San Diego IRB-approved research (except where necessary to avoid
immediate hazard to subjects);
iii. Implementing any
changes to exempt research that could affect exempt status; or
iv. Continuing a project
beyond its approval period (if applicable).
4. Obtain permission of
the IO or designee when seeking to either rely on the IRB review of another
institution or extend a UC San Diego IRB's review to cover activities at
another institution.
5. Obtain approvals from
committees, offices, or entities other than the IRB, as required by applicable
policy, law or regulations.
6. Maintain control of and
accountability for test articles used in clinical investigations except when
another authorized entity (e.g., Pharmacy) has accepted such responsibility.
7. Conduct the research according
to the approved protocol, the requirements of the IRB and other review entities,
and applicable laws, policies, and regulations.
8. Delegate responsibility
for tasks only to qualified individuals and ensure adequate training and
supervision of those individuals.
9. Obtain and document
informed consent as required.
i. Notify subjects of new
information that may be relevant to their safety, rights, or willingness to
continue participation.
ii. Consider consent an
ongoing process.
10. Continuously evaluate
and manage problems and deviations.
i. Report as required to
the IRB and/or other entities.
ii. Respond promptly to
questions, concerns or complaints from subjects.
iii. Promptly take remedial
action in the event of non-compliance with established protocols or any other
act or omission that unduly threatens the health or welfare of human research subjects.
11. Report completion of
non-exempt human subjects research to the IRB.
12.
Maintain
documentation sufficient to establish compliance with this policy and all
directions from the IRB and OIA and maintain all other records required by
University policy, and regulatory and contractual requirements.
e) Department Chairs/Unit
Heads
1. Provide oversight of
research conducted by study personnel in their departments or units.
2. Verify or confirm eligibility
and sufficient resources to conduct research.
3. Permit use of
facilities, personnel, or resources only with appropriate approvals and in
accordance with University policy and practice and the ethical standards of
their discipline.
4. Facilitate and value
IRB service by members of their departments or units.
5. Supervise and
discipline researchers, as appropriate, for noncompliance or non-performance.
f) Office of IRB
Administration
1. Develop forms, templates,
and guidance and make those materials easily accessible so that researchers are
able to:
i. Understand whether this
Policy applies to their activities
ii. Understand and carry
out their responsibilities
iii. Provide clear and
timely information needed for effective IRB review
iv. Cross-reference
information already collected elsewhere
v. Receive information
about new requirements related to human research subjects protection.
2. Establish, maintain, and
document procedures and systems by which submissions are received and routed in
a timely fashion and tracked appropriately.
3. Enhance the effective
use of IRB member time and effort by implementing procedures to:
i. Assign appropriate
level of review
ii. Screen for incomplete
submissions and conduct pre-review
iii. Conduct administrative
and expedited reviews
iv. Keep IRB reviews within
proper authority
v. Refer matters outside
IRB jurisdiction to appropriate offices or processes.
4. Produce professional,
clear and prompt communication on behalf of the IRBs.
5. Maintain documentation
according to University and regulatory requirements.
6. Contribute to training,
education, and communication about human subject protection.
7. Coordinate with other
review processes involved in protection of human subjects.
8. Serve as a contact for
questions, concerns, or suggestions from subjects.
PROCEDURES
N/A
FORMS
N/A
RELATED
INFORMATION
University of
California – Protection of Human Subjects in Research
Belmont Report: Ethical
Principles and Guidelines for the Protection of Human Subjects of Research,
Report of the National Commission for the Protection of Human Subjects of
Biomedical and Behavioral Research, Federal Register. 44 (76): 23191–7 (April 1,
1979).
Code of Federal
Regulations, Title 45 (Department of Health & Human Services), Part 46
Code of
Federal Regulations, Title 21 (Food & Drug Administration), Parts 50, 56, 312 and 812
California Health and
Safety Code: Human Experimentation (Sections 24170-24179.5)
Contracts & Grants
Manual Chapter 18, University of California Office of the President
Terms of Federalwide
Assurance
FREQUENTLY
ASKED QUESTIONS (FAQs)
N/A
REVISION
HISTORY
03/09/2021 -
Previous version rescinded and completely rewritten and reformatted.